{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:41Z","timestamp":1790916821566,"version":"4.1.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"name":"2024 Pharmaceutical Science and Technology Research Project of Chinese Medicine Education Association","award":["2024KTM032"],"award-info":[{"award-number":["2024KTM032"]}]},{"name":"2025 Special Research Project on High-Quality Development of Hospitals and Pharmaceutical Innovation of Chinese Medicine Education Assciation","award":["2025-PJZXKT-10"],"award-info":[{"award-number":["2025-PJZXKT-10"]}]},{"name":"Youth Talent Support Project of Tianshan Talents Training Program of Xinjiang Uygur Autonomous Region","award":["2024TSYCQNTJ0046"],"award-info":[{"award-number":["2024TSYCQNTJ0046"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This study analyzed the correlation and differences between the gene polymorphisms of ATP-binding cassette B1 (\n                      <jats:italic toggle=\"yes\">ABCB1<\/jats:italic>\n                      ), which encode the efflux drug transporter P-glycoprotein, and the efficacy and plasma concentration of perampanel (PER) in patients with refractory epilepsy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Plasma samples were collected from 115 patients with epilepsy who received PER treatment for at least 21 days. The\n                      <jats:italic toggle=\"yes\">ABCB1<\/jats:italic>\n                      genotypes were detected using first-generation Sanger sequencing, and the PER plasma concentration was measured using ultra-high performance liquid chromatography-mass spectrometry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall efficacy of PER in treating patients with refractory epilepsy was observed in 64.3% of patients. The\n                      <jats:italic toggle=\"yes\">ABCB1<\/jats:italic>\n                      rs2032582 gene polymorphisms were significantly associated with the therapeutic efficacy of PER in refractory epilepsy. When compared with patients with the wild-type homozygous genotype, the plasma concentrations of PER were significantly higher for patients with the P-glycoprotein-encoding\n                      <jats:italic toggle=\"yes\">ABCB1<\/jats:italic>\n                      rs2032582 and\n                      <jats:italic toggle=\"yes\">ABCB1<\/jats:italic>\n                      rs1045642 mutant genotypes (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.05). When the plasma concentration of PER exceeded 305\u2009ng\/ml, patients more effectively responded to PER treatment (area under the curve: 0.614,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">ABCB1<\/jats:italic>\n                      gene polymorphisms are important predictors of effective with PER treatment and serve as factors that affect the achievement of therapeutic plasma concentrations of PER, and they have contrasting effects.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000614","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:01:15Z","timestamp":1784538075000},"page":"276-289","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Individualized perampanel response and efficacy in patients with refractory epilepsy: the need for ATP-binding cassette B1 genotyping and therapeutic drug monitoring to work in tandem"],"prefix":"10.1097","volume":"36","author":[{"given":"Ting","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Xinjiang Medical University, Xinjiang Key Laboratory of Biopharmaceuticals and Medical Devices"},{"name":"Department of Pharmacy"},{"name":"Institute of Clinical Pharmacy of Xinjiang Uygur Autonomous Region, People\u2019s Hospital of Xinjiang Uygur Autonomous Region"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-jian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute of Clinical Pharmacy of Xinjiang Uygur Autonomous Region, People\u2019s Hospital of Xinjiang Uygur Autonomous Region"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-lan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"},{"name":"Institute of Clinical Pharmacy of Xinjiang Uygur Autonomous Region, People\u2019s Hospital of Xinjiang Uygur Autonomous Region"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xinjiang Hospital of Beijing Children\u2019s Hospital, Children\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xinjiang Hospital of Beijing Children\u2019s Hospital, Children\u2019s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-hai","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Feng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Xinjiang Medical University, Xinjiang Key Laboratory of Biopharmaceuticals and Medical Devices"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"R1-20261002","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MS9.0000000000004295","article-title":"Breaking the resistance: a narrative review of the evolution from traditional drugs to precision therapies in epilepsy.","volume":"88","author":"Patel","year":"2025","journal-title":"Ann Med Surg"},{"key":"R2-20261002","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S1474-4422(23)00151-5","article-title":"Drug resistance in epilepsy.","volume":"22","author":"Perucca","year":"2023","journal-title":"Lancet Neurol"},{"key":"R3-20261002","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.neurol.2021.10.005","article-title":"Perception of seizure severity and bothersome in refractory focal epilepsy.","volume":"178","author":"Tedrus","year":"2022","journal-title":"Rev Neurol (Paris)"},{"key":"R4-20261002","doi-asserted-by":"crossref","first-page":"11696","DOI":"10.3390\/ijms222111696","article-title":"Pharmacogenetics of drug-resistant epilepsy (review of literature).","volume":"22","author":"Smolarz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R5-20261002","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/13543776.2019.1618273","article-title":"An updated patent review on P-glycoprotein inhibitors (2011\u20132018).","volume":"29","author":"Leopoldo","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"R6-20261002","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/jnc.13498","article-title":"Inhibition of p38 mitogen-acti\u2010vated protein kinase signaling reduces multidrug transporter activity and anti-epileptic drug resistance in refractory epileptic rats.","volume":"136","author":"Shao","year":"2016","journal-title":"J Neurochem"},{"key":"R7-20261002","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10928-017-9549-6","article-title":"Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1.","volume":"44","author":"Tran","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R8-20261002","doi-asserted-by":"crossref","first-page":"643","DOI":"10.17816\/PAVLOVJ680637","article-title":"Structural and functional biochemistry of OATP1B3: from polymorphisms to therapeutic targets.","volume":"33","author":"Abalenikhina","year":"2025","journal-title":"I. P. Pavlov Russ. Med. Biol. Herald"},{"key":"R9-20261002","doi-asserted-by":"crossref","first-page":"107322","DOI":"10.1016\/j.ejps.2025.107322","article-title":"Effects of nonsense genetic variants on OATP1B1 expression and transport activity in vitro.","volume":"215","author":"Kiander","year":"2025","journal-title":"Eur J Pharm Sci"},{"key":"R10-20261002","first-page":"2372","article-title":"The effect of miR-146a gene silencing on drug-resistance and expression of protein of P-gp and MRP1 in epilepsy.","volume":"22","author":"Zhang","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R11-20261002","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/1567202616666191023160201","article-title":"MicroRNA-542-3p regulates P-glycoprotein expression in rat epilepsy via the toll-like receptor 4\/nuclear factor-kappaB signaling pathway.","volume":"16","author":"Yan","year":"2019","journal-title":"Curr Neurovasc Res"},{"key":"R12-20261002","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eplepsyres.2015.05.015","article-title":"ABCB1 G2677T\/A polymorphism is associated with the risk of drug-resistant epilepsy in Asians.","volume":"115","author":"Yu","year":"2015","journal-title":"Epilepsy Res"},{"key":"R13-20261002","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.seizure.2017.07.015","article-title":"Effects of ABCB1, ABCC2, UGT2B7 and HNF4 genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy.","volume":"51","author":"Shen","year":"2017","journal-title":"Seizure"},{"key":"R14-20261002","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s00381-021-05146-3","article-title":"miR-23a-3p is involved in drug resistance by directly targeting the influx drug transporter organic anion-transporting polypeptide 2.","volume":"37","author":"Guo","year":"2021","journal-title":"Childs Nerv Syst"},{"key":"R15-20261002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1684\/epd.2020.1165","article-title":"Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study.","volume":"22","author":"Liguori","year":"2020","journal-title":"Epileptic Disord"},{"key":"R16-20261002","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/epi4.12398","article-title":"Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: the open-label study 342 (FREEDOM Study).","volume":"5","author":"Yamamoto","year":"2020","journal-title":"Epilepsia Open"},{"key":"R17-20261002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14737175.2019.1555474","article-title":"Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.","volume":"19","author":"Tyrlikova","year":"2019","journal-title":"Expert Rev Neurother"},{"key":"R18-20261002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1684\/epd.2020.1165","article-title":"Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study.","volume":"22","author":"Liguori","year":"2020","journal-title":"Epileptic Disord"},{"key":"R19-20261002","doi-asserted-by":"crossref","first-page":"e5446","DOI":"10.1002\/bmc.5446","article-title":"Development and application of a novel LC-MS\/MS method for human plasma concentration monitoring of perampanel in pediatric epilepsy patients.","volume":"36","author":"Zhao","year":"2022","journal-title":"Biomed Chromatogr"},{"key":"R20-20261002","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10072-024-07798-w","article-title":"Effectiveness and safety of perampanel in refractory status epilepticus: a case series.","volume":"46","author":"Renna","year":"2024","journal-title":"Neurol Sci"},{"key":"R21-20261002","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s12028-024-02019-w","article-title":"Perampanel as an add-on therapy in patients with refractory status epilepticus and postanoxic encephalopathy: a real-life single-center retrospective cohort study.","volume":"41","author":"Cutillo","year":"2024","journal-title":"Neurocrit Care"},{"key":"R22-20261002","doi-asserted-by":"crossref","first-page":"110655","DOI":"10.1016\/j.yebeh.2025.110655","article-title":"Efficacy and safety of perampanel in critically ill patients with refractory and super-refractory status epilepticus: a retrospective study from a Chinese tertiary medical center.","volume":"172","author":"Qu","year":"2025","journal-title":"Epilepsy Behav"},{"key":"R23-20261002","doi-asserted-by":"crossref","first-page":"e70968","DOI":"10.1002\/brb3.70968","article-title":"Effectiveness and safety of perampanel in refractory focal epilepsy: real-world evidence from a chinese cohort.","volume":"15","author":"Yi","year":"2025","journal-title":"Brain Behav"},{"key":"R24-20261002","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/FTD.0000000000000416","article-title":"Therapeutic drug monitoring for perampanel in Japanese epilepsy patients: influence of concomitant antiepileptic drugs.","volume":"39","author":"Yamamoto","year":"2017","journal-title":"Ther Drug Monit"},{"key":"R25-20261002","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/FTD.0000000000001101","article-title":"Therapeutic drug monitoring of perampanel in children with refractory epilepsy: focus on influencing factors on the free-perampanel concentration.","volume":"45","author":"Qu","year":"2023","journal-title":"Ther Drug Monit"},{"key":"R26-20261002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.seizure.2019.10.023","article-title":"Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years.","volume":"73","author":"Ikemoto","year":"2019","journal-title":"Seizure"},{"key":"R27-20261002","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.yebeh.2019.02.004","article-title":"Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.","volume":"94","author":"Ishikawa","year":"2019","journal-title":"Epilepsy Behav"},{"key":"R28-20261002","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1517\/14656566.8.10.1441","article-title":"Multidrug resistance in epilepsy: a pharmacogenomic update.","volume":"8","author":"Tate","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R29-20261002","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-1-0716-1554-6_8","article-title":"The structure and mechanism of drug transporters.","volume":"2342","author":"Roberts","year":"2021","journal-title":"Methods Mol Biol"},{"key":"R30-20261002","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1002\/cpph.46","article-title":"Overview of transporters in pharmacokinetics and drug discovery.","volume":"82","author":"Zhang","year":"2018","journal-title":"Curr Protoc Pharmacol"},{"key":"R31-20261002","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd4461","article-title":"What do drug transporters really do?","volume":"14","author":"Nigam","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"R32-20261002","doi-asserted-by":"crossref","first-page":"266","DOI":"10.30683\/1929-2279.2025.14.27","article-title":"Genomic and proteomic insights into abc transporter-mediated drug resistance in cancer.","volume":"14","author":"Krubaa","year":"2025","journal-title":"J Can Res Updates"},{"key":"R33-20261002","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/0022-3859.138739","article-title":"Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to antiepileptic drugs.","volume":"60","author":"Taur","year":"2014","journal-title":"J Postgrad Med"},{"key":"R34-20261002","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eplepsyres.2015.05.015","article-title":"ABCB1 G2677T\/A polymorphism is associated with the risk of drug-resistant epilepsy in Asians.","volume":"115","author":"Yu","year":"2015","journal-title":"Epilepsy Res"},{"key":"R35-20261002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12993-016-0106-z","article-title":"Association between C3435T polymorphism of MDR1 gene and the incidence of drug-resistant epilepsy in the population of Polish children.","volume":"12","author":"Stasio\u0142ek","year":"2016","journal-title":"Behav Brain Funct"},{"key":"R36-20261002","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FTD.0b013e31826517c6","article-title":"Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy.","volume":"34","author":"Lovri\u0107","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R37-20261002","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10928-017-9549-6","article-title":"Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1.","volume":"44","author":"Tran","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R38-20261002","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.09.001","article-title":"Effects of CYP3A4\/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.","volume":"117","author":"Wang","year":"2015","journal-title":"Epilepsy Res"},{"key":"R39-20261002","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.seizure.2017.07.015","article-title":"Effects of ABCB1, ABCC2, UGT2B7 and HNF4 genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy.","volume":"51","author":"Shen","year":"2017","journal-title":"Seizure"},{"key":"R40-20261002","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/FTD.0000000000000805","article-title":"Impact of ABCB1 polymorphism on levetiracetam serum concentrations in epileptic uygur children in China.","volume":"42","author":"Zhao","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R41-20261002","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/FTD.0000000000000927","article-title":"Impact Of ABCB1 polymorphisms on lacosamide serum concentrations in uygur patients with epilepsy in China.","volume":"44","author":"Zhao","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R42-20261002","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.seizure.2011.04.003","article-title":"Lack of association of ABCB1 haplotypes on five loci with response to treatment in epilepsy.","volume":"20","author":"Haerian","year":"2011","journal-title":"Seizure"},{"key":"R43-20261002","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.brainres.2011.03.028","article-title":"Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: an analysis in a western Chinese pediatric population.","volume":"1391","author":"Dong","year":"2011","journal-title":"Brain Res"},{"key":"R44-20261002","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.eplepsyres.2018.12.003","article-title":"Potential protein-binding displacement interactions with perampanel: An in vitro analysis.","volume":"149","author":"Gidal","year":"2018","journal-title":"Epilepsy Res"},{"key":"R45-20261002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40780-025-00537-z","article-title":"Placental transfer of third-generation antiepileptic drugs: in vivo lacosamide case study and in vitro investigation of transporter inhibition by lacosamide and perampanel.","volume":"12","author":"Ueda","year":"2026","journal-title":"J Pharm Health Care Sci"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:00:14Z","timestamp":1790913614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000614","relation":{},"ISSN":["1744-6872","1744-6880"],"issn-type":[{"value":"1744-6872","type":"print"},{"value":"1744-6880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"2026-04-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}